Sutro Biopharma, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for STRO, updated each market day.
STRO AI Sentiment
AI sees no strong directional signal for Sutro Biopharma, Inc. stock over the next 10 market days.
Prediction date: Sept. 21, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Sutro Biopharma, Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Sector
Exchange
Market Cap
$256,676,527
Cap Tier
Employees
128
Headquarters
SOUTH SAN FRANCISCO, CA
Listed Since
Sept. 27, 2018
Website
STRO Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
STRO Volatility
Sutro Biopharma, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
